Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients

Fig. 2

Kaplan-Meier plot of time to withdrawal for any reason and due to lack of efficacy or adverse event from start of the randomized controlled trial (RCT) for the certolizumab pegol (CZP) intention-to-treat (ITT) population (n =492). AE adverse event, MTX methotrexate, OLE open-label extension

Back to article page